REFERENCES
1. Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol 2018;28:321-31.
2. Zaki P, Chuong MD, Schaub SK, Lo SS, Ibrahim M, Apisarnthanarax S. Proton beam therapy and photon-based magnetic resonance image-guided radiation therapy: the next frontiers of radiation therapy for hepatocellular carcinoma. Technol Cancer Res Treat 2023;22:15330338231206335.
3. Liu Y, Chou B, Yalamanchili A, Lim SN, Dawson LA, Thomas TO. Local therapies for hepatocellular carcinoma and role of MRI-guided adaptive radiation therapy. J Clin Med 2023;12:3517.
4. Guo B, Stephans K, Woody N, Antolak A, Moazzezi M, Xia P. Online verification of breath-hold reproducibility using kV-triggered imaging for liver stereotactic body radiation therapy. J Appl Clin Med Phys 2023;24:e14045.
5. Dawson LA, Winter KA, Knox JJ, et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). JCO 2023;41:489-489.
6. Craig T, Xiao Y, McNulty S, Dawson LA. Insights from image guided radiation therapy credentialing for the NRG oncology RTOG 1112 liver stereotactic body radiation therapy trial. Pract Radiat Oncol 2023;13:239-45.
7. Yang JF, Lo CH, Lee MS, et al. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180.
8. Lin Q, Zhou N, Zhu X, et al. Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis. J Radiat Res 2022;63:272-80.
9. Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and radiation-immunotherapy combination. Cancers 2021;13:192.
10. Schaub SK, Hartvigson PE, Lock MI, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies. Technol Cancer Res Treat 2018;17:1533033818790217.
11. Sayan M, Yegya-Raman N, Greco SH, et al. Rethinking the role of radiation therapy in the treatment of unresectable hepatocellular carcinoma: a data driven treatment algorithm for optimizing outcomes. Front Oncol 2019;9:345.
12. Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33.
13. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 2022;12:28-51.
14. Van Oirschot M, Bergman A, Verbakel WFAR, et al. Determining planning priorities for SABR for oligometastatic disease: a secondary analysis of the SABR-COMET phase II randomized trial. Int J Radiat Oncol Biol Phys 2022;114:1016-21.
15. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
16. Roberts HJ, Hong TS. Proton versus photon radiotherapy for hepatocellular carcinoma: current data and technical considerations. J Radiosurgery SBRT 2023;9:9-16.
17. Cheng JY, Liu CM, Wang YM, et al. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol 2020;15:159.
18. NRG oncology. A phase III randomized trial of protons versus photons for hepatocellular carcinoma. Available from: https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gi003?filter=nrg-gi003. [Last accessed on 22 Nov 2024].
19. Byun HK, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2023;29:945-57.
20. Yoon SM, Kim SY, Lim YS, et al. Stereotactic body radiation therapy for small (≤ 5 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15.
21. Li LQ, Su TS, Wu QY, Lin ZT, Liang SX. Therapeutic outcome of stereotactic body radiotherapy for small hepatocellular carcinoma lesions - a systematic review and network meta-analysis. Clin Oncol 2023;35:652-64.
22. Bush DA, Volk M, Smith JC, et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial. Cancer 2023;129:3554-63.
23. Méndez Romero A, van der Holt B, Willemssen FEJA, et al. Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial). Int J Radiat Oncol Biol Phys 2023;117:45-52.
24. Comito T, Loi M, Franzese C, et al. Stereotactic radiotherapy after incomplete transarterial (chemo-) embolization (TAE\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360). Curr Oncol 2022;29:8802-13.
25. Su CW, Teng W, Shen EY, et al. Concurrent atezolizumab plus bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma. Oncologist 2024;29:e922-31.
26. Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2018;25:3308-15.
27. Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661-9.
28. Mähringer-Kunz A, Steinle V, Düber C, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int 2019;39:324-31.
29. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 2020;6:e204564.
30. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-73.
31. Sangro B, Chan SL, Kelley RK, et al; HIMALAYA investigators. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 2024;35:448-57.
32. Lin Q, Huang X, Zhong C, Luo T, Zeng X, Chen S. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: a propensity-matched analysis of surveillance, epidemiology, and end results database. Cancer Med 2019;8:515-26.
33. Rim CH, Jeong BK, Kim TH, Hee Kim J, Kang HC, Seong J. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). Int J Radiat Biol 2020;96:759-66.
34. Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Rep 2022;4:100498.
35. Tojjari A, Yu J, Saeed A. Immunotherapy and radiation therapy combinatorial approaches in hepatocellular carcinoma. Cancers 2024;16:1058.
36. Reiss KA, Wattenberg MM, Damjanov N, et al. A pilot study of galunisertib plus stereotactic body radiotherapy in patients with advanced hepatocellular carcinoma. Mol Cancer Ther 2021;20:389-97.
37. Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015;21:3462-71.
38. Guo L, Wei X, Feng S, et al. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial. Hepatol Int 2022;16:1368-78.
39. Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC). Cancers 2022;14:4383.
41. Chen L, Zhang R, Lin Z, Tan Q, Huang Z, Liang B. Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Front Immunol 2023;14:1100079.
42. Yang Y, Xiong L, Li M, Jiang P, Wang J, Li C. Advances in radiotherapy and immunity in hepatocellular carcinoma. J Transl Med 2023;21:526.
43. Su K, Wang F, Li X, et al. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period. Front Immunol 2023;14:1265959.
44. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020;38:2830-8.
45. Toesca DAS, Osmundson EC, von Eyben R, Shaffer JL, Koong AC, Chang DT. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol 2017;7:173-82.
46. Upadhyay R, Doe N, Gokun Y, et al. Outcomes and predictors of toxicity after stereotactic body radiotherapy for child-pugh B or C hepatocellular carcinoma in a fiducial-less setting. Int J Radiat Oncol Biol Phys 2024;120:e489.
47. Sanford NN, Pursley J, Noe B, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys 2019;105:64-72.
48. Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with child-pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.
49. Thomas TO, Hasan S, Small W Jr, et al. The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol 2014;5:236-46.
50. Klein J, Dawson LA, Jiang H, et al. Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2015;93:16-25.
